Nishan M. DeSilva - 13 Nov 2023 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Director
Signature
Matthew Bartholomae, Attorney-in-Fact for Nishan de Silva
Issuer symbol
RNAC
Transactions as of
13 Nov 2023
Net transactions value
-$69,750
Form type
4
Filing time
15 Nov 2023, 17:18:52 UTC
Previous filing
04 Jan 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SELB Stock Option (Right to Buy) Disposed to Issuer -80,000 -100% 0 13 Nov 2023 Common Stock 80,000 $4.57 Direct F1
transaction SELB Stock Option (Right to Buy) Disposed to Issuer -40,000 -100% 0 13 Nov 2023 Common Stock 40,000 $3.31 Direct F2
transaction SELB Stock Option (Right to Buy) Disposed to Issuer $69,750 -75,000 -100% $0.9300 0 13 Nov 2023 Common Stock 75,000 $1.13 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 23, 2021, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.
F2 This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.
F3 This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.